Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Deliver mOre aPplications for More Durable Pulmonary Vein IsOlation

NCT: NCT07021313 · ACTIVE_NOT_RECRUITING

NCT IDNCT07021313
StatusACTIVE_NOT_RECRUITING
Start Date2025-06-30
Completion2028-06
SponsorR&D Cardiologie (OTHER)
First posted
Last updated

Brief Summary

Pulmonary vein isolation (PVI) by catheter ablation (CA) has become a widely accepted interventional treatment for patients with symptomatic atrial fibrillation (AF) despite anti-arrhythmic drugs (AAD). Classic thermal ablation modalities use radiofrequency energy or cryo-energy to create cardiac tissue lesions. Irreversible electroporation (IRE) using pulsed field energy (PFA) is a novel technology for cardiac tissue ablation. Initial studies have shown favorable outcome data in patients with AF treated by performing PVI using PFA. However, the freedom of AF has not yet proven superior to existing thermal ablation methods and appears similarly associated with suboptimal lesion durability, leading to electrical reconnection. The purpose of this study is to determine if freedom of atrial fibrillation may be improved by delivering more and better targeted pulsed field ablations.

Frequently Asked Questions

What is Deliver mOre aPplications for More Durable Pulmonary Vein IsOlation?

Deliver mOre aPplications for More Durable Pulmonary Vein IsOlation is a clinical trial registered under NCT07021313. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT07021313?

The current status of NCT07021313 (Deliver mOre aPplications for More Durable Pulmonary Vein IsOlation) is: ACTIVE_NOT_RECRUITING.

When did Deliver mOre aPplications for More Durable Pulmonary Vein IsOlation start?

Deliver mOre aPplications for More Durable Pulmonary Vein IsOlation started on 2025-06-30.

Related Devices

PMA P230017Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible ElectroporationMedtronic, Inc. PMA P230030Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible ElectroporationFarapulse, Inc. PMA P240006Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible ElectroporationBiosense Webster, Inc. PMA P240013Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible ElectroporationMedtronic, Inc. PMA P240044Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible ElectroporationKardium, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑